Aequus Announces Giovanni Di Genova Joining Board of Directors
(TheNewswire)
VANCOUVER, September 22 nd , 2025 – TheNewswire - AequusPharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”),a specialty pharmaceutical company focused on bringing healthcaresolutions to Canadians through licensing and partnerships, is pleased to announce Giovanni Di Genova has agreed to join the AequusBoard of Directors, subject to the completion of his PIF and TSXapproval, effective Friday September 12 th , 2025.
“Aequus is pleased to welcome Giovanni Di Genova as a new director and we are eager to work with him on
the future ahead.” Said Doug Janzen, Aequus Chairman & CEO. ABOUTGIOVANNI DI GENOVA
Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and
Université de Montréal, respectively. He began hiscareer in the specialty compounding pharmacy & pharmaceuticalindustry nearly 35 years ago, covering multiple therapeutic areasincluding ophthalmology, oncology, gastrointestinal, neurological,infectious, and autoimmune diseases. John has held positions in bothinnovative and generic pharmaceutical organizations, with roles inAPI/Materials Management, Production, Sales, Marketing and BusinessDevelopment. He has a proven track record in strategy and operations,including strong business development experience with M&A,licensing, co-development, and supply agreements. John started hiscareer at Ayerst and PharmaScience, and most recently, served as CEOand founder of Advanced Dosage Forms, a private firm involved in thelicensing, sales, marketing, and distribution ofhigh-barrier-to-market niche pharmaceuticals.
ABOUT AEQUUS PHARMACEUTICALS INC.
Aequus Pharmaceuticals Inc. (TSX-V: AQS ) is aspecialty pharmaceutical company, with a focus on commercializingvalue-added products in specialty therapeutic areas in the Canadianmarket.
FORWARD-LOOKING STATEMENT DISCLAIMER
This release may contain forward-looking statements orforward-looking information under applicable Canadian securitieslegislation that may not be based on historical fact, including,without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”,“anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of ourexperience and perception of historical trends,current conditions and expected future developments, as well as thefactors we believe are appropriate. Forward- looking statementsinclude but are not limited to statements relating to: the penetrationand growth of ZIMED® PF following its launch, the benefits of the transaction and improvement of Aequus’ financial outlook, the anticipatedmeeting date in respect of the shareholder meeting, completion of thetransaction and the timing thereof. Such statements reflect our current views with respect to future events and are subject to risks
and uncertainties and are necessarily based upon anumber of estimates and assumptions that, while considered reasonableby Aequus, are inherently subject to significant business, economic,competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements tobe materially different from any future results, performance, orachievements that may be expressed or implied by such forward-lookingstatements. In making the forward-looking statements included in thisrelease, the Company has made various material assumptions, including,but not limited to: obtaining regulatory and shareholder approvals; satisfaction of other conditions to the consummation of the proposed transaction on the proposed terms and schedule;general business and economic conditions; the Company’s ability to successfully out license or sell its current product and in-license or develop new products; the assumption that theCompany’s current good relationships with third parties will bemaintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; the impact of global events on the Company’soperations; and the Company’s ability to protect patents andproprietary rights. In evaluating forward looking statements, currentand prospective shareholders should specifically consider variousfactors set out herein and under the heading “Risk Factors” inAequus’ latest annual Management’s Discussion and Analysis, a copy of which is available on Aequus’ profileon SEDAR+ at www.sedarplus.ca and as otherwisedisclosed from time to time on Aequus’ SEDAR+ profile. Should one ormore of these risks or uncertainties, or a risk that is not currentlyknown to us materialize, or should assumptionsunderlying those forward-looking statements prove incorrect, actualresults may vary materially from those described herein. Theseforward-looking statements are made as of the date of this release andwe do not intend, and do not assume any obligation, to update theseforward-looking statements, except as required by applicablesecurities laws. Investors are cautioned that forward-lookingstatements are not guarantees of future performance and areinherently uncertain. Accordingly, investors arecautioned not to put undue reliance on forwardlooking statements.Neither TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this release.
Aequus Investor Relations
Email: investors@aequuspharma.ca Phone:604-336-7906
Copyright (c) 2025 TheNewswire - All rights reserved.
NASDAQ: AQS:CC
AQS:CC Trading
-13.33% G/L:
$0.065 Last:
14,501 Volume:
$0.07 Open:
